Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Bartlett, John M S ^a,b   Thomas, Jeremy ^b   Ross, Douglas T ^c   Seitz, Robert S ^c   Ring, Brian Z ^c   Beck, Rodney A ^c   Pedersen, Hans Christian ^a   Munro, Alison ^a   Kunkler, Ian H ^b   Campbell, Fiona M ^a   Jack, Wilma ^b   Kerr, Gillian R ^b   Johnstone, Laura ^a   Cameron, David A ^b   Chetty, Udi ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c Clarient Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN CEACAM5; PROTEIN HTF9C; PROTEIN NDRG1; PROTEIN P53; PROTEIN SLC7A5; TAMOXIFEN; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARCINOEMBRYONIC ANTIGEN; CEACAM5 PROTEIN, HUMAN; CELL CYCLE PROTEIN; ESTROGEN RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; N MYC DOWNSTREAM REGULATED GENE 1 PROTEIN; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; POSTMENOPAUSE; POSTOPERATIVE CARE; RECURRENCE RISK; SCORING SYSTEM; TISSUE MICROARRAY; TREATMENT PLANNING; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DIAGNOSTIC TEST; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CELL CYCLE PROTEINS; CHEMOTHERAPY, ADJUVANT; DIAGNOSTIC TESTS, ROUTINE; DISEASE-FREE SURVIVAL; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650892625     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2604     Document Type: Article

References (21)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
2. Pancholi S, Lykkesfeldt A, Johnston SR, Dowsett M, Martin LA. The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90(RSK) in tamoxifen-resistant MCF-7 cells. Breast Cancer Res 2005, 7:P2.08.
3. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081. 10.1056/NEJMoa040331, 15014181.
4. Hughes-Davies L, Caldas C, Wishart GC. Tamoxifen: the drug that came in from the cold. Br J Cancer 2009, 101:875-878. 10.1038/sj.bjc.6605231, 2743359, 19672259.
5. Seruga B, Tannock IF. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 2009, 27:840-842. 10.1200/JCO.2008.19.5594, 19139426.
6. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2008, 112:700-709. 10.1002/cncr.23193, 18072256.
7. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
8. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999, 31:209-223. 10.1016/S1040-8428(99)00034-7, 10532196.
9. Ravdin PM. Adjuvant! Version 5. Underlying data and assumptions. Breast Cancer Res Treat 2003, 82:321.
10. Desmedt C, Sotiriou C. When should I start using a new biomarker: Focus on Expression arrays (vol 5, pg 97, 2007). Eur J Cancer 2008, 44:326-328.
11. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
12. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, van de Vijver MJ, Bergh J, Piccart MT, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272. 10.1093/jnci/djj052, 16478745.
13. van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
15. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MCU, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3039-3047. 10.1200/JCO.2006.05.6564, 16809728.
16. Ross DT, Kim C-Y, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N. Chemosensitivity and stratification by a five monoclonal andibody immunohistochemistry test in the NASBP B14 and B20 trials. Clin Cancer Res 2008, 14:6602-6609. 10.1158/1078-0432.CCR-08-0647, 2722068, 18927301.
17. Thomas JS, Kerr GR, Jack WJL, Campbell F, Mckay L, Pedersen HC, Kunkler IH, Cameron DA, Chetty U, Bartlett JMS. Histological grading of invasive breast carcinoma - a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology 2009, 55:724-731. 10.1111/j.1365-2559.2009.03429.x, 19845790.
18. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005, 97:1808-1815. 10.1093/jnci/dji427, 16368942.
19. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003, 63:1445-1448.
20. Bartlett JMS, Campbell FM, Ibrahim M, Thomas J, Wenyck I, Ellis IO, Kay E, Connolly Y, O'Grady A, Cunningham P, Barnett S, Starczynski J, Miller K. A UK NEQAS ring study evaluating observer variation in the diagnosis of HER2 amplification using the Kreatech (TM) HER2 FISH probe. Cancer Res 2009, 69:206S.
21. Bartlett JMS, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Connolly Y, Campbell F, O'Grady A, Barnett S, Miller K. External quality assurance of HER2 FISH and ISH testing three years of the UK National External Quality Assurance Scheme. Am J Clin Pathol 2009, 131:106-111. 10.1309/AJCPLN78ZQXEMNMA, 19095573.